OB First Weeks of 2017 to Investor group Final

The Center for Drug Research and Development

We recently traveled to Vancouver and had a very successful and enlightening meeting with The Center for Drug Research and Development (CDRD). They are now officially working with us to create a program to specifically test OB’s compounds. We are developing a budget and a series of milestones that we will achieve with CDRD’s help. This first work will focus on toxicity, metabolism and formulation for our administered compounds. We are excited to work with this group and hope this testing is the first in a series of milestones that CDRD will help OB accomplish. Their facility at UBC is very impressive and they have shown a keen interest in our work. New investment dollars currently coming in will advance our relationship with CDRD. CDRD is sufficiently interested in OB that it is willing to take equity for 50% of the research budget.

Non-Confidential Executive Summary May 2017

F o r w a r d  L o o k i n g  S t a t e m e n t s

This presentation may contain forward-looking statements and information which may include forward looking statements and use terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward looking statements are based on our current expectations and certain assumptions which may be subject to a variety of risks and uncertainties. These statements are not guarantees of future performance and the results actually achieved by OB Pharma may substantially differ from these forward looking statements. OB Pharma assumes no obligation to update these forward looking statements or to correct them in case of developments which differ from those anticipated.

Neurobiology of Disease

The loss of interneuron functional diversity in the piriform cortex after induction of experimental epilepsy

Interneuronal functional diversity is thought to be an important factor in the control of neural network oscillations in many brain regions. Specifically, interneuron action potential firing patterns are thought to modulate brain rhythms. In neurological disorders such as epilepsy where brain rhythms are significantly disturbed interneuron function is largely unexplored. Thus the purpose of this study was to examine the functional diversity of piriform cortex interneurons (PC; an area of the brain that easily supports seizures) before and after kindling-induced epilepsy. Using cluster analysis, we found five control firing behaviors. These groups were termed: non-adapting very high frequency (NAvHF), adapting high frequency (AHF), adapting low frequency (ALF), strongly adapting low frequency (sALF), and weakly adapting low frequency (wALF).

Frontiers in Neural Circuits

Zeinab Birjandian , Chakravarthi Narla and Michael O. Poulter

The inhibition of excitatory (pyramidal) neurons directly dampens their activity resulting in a suppression of neural network output. The inhibition of inhibitory cells is more complex. Inhibitory drive is known to gate neural network synchrony, but there is also a widely held view that it may augment excitability by reducing inhibitory cell activity, a process termed disinhibition. Surprisingly, however, disinhibition has never been demonstrated to be an important mechanism that augments or drives the activity of excitatory neurons in a functioning neural circuit. Using voltage sensitive dye imaging (VSDI) we show that 20–80 Hz stimulus trains, β–γ activation, of the olfactory cortex pyramidal cells in layer II leads to a subsequent reduction in inhibitory interneuron activity that augments the efficacy of the initial stimulus

OB Pharmaceuticals Logo OB download